The DOI matches its Crossref record.
Cannabinoids as Therapeutic Agents
Abstract
s of Papers, 188th Meet. American Chemical Soc., Philadelphia, August 1984, American Chemical Society, Washington, D.C., 1984; Abstr. MEDI,45. 35. Melvin, L. S., Johnson, M. R., and Milne, G. M., CP-55,244: a cannabinoid derived analgetic, in Abstracts of Papers, 186th Meet. American Chemical Soc., Washington, D.C., August 1983, American Chemical Society, Washington, D.C., 1983; Abstr. MEDI, 22. 36. Johnson, M. R., Eggler, J. F., Melvin, L. S., and Milne, G. M., Cannabinoid-derived therapeutants: further studies in the search for non-addicting drugs to relieve pain and discomfort, in Abstracts of Papers, 186th Meet, of the American Chemical Soc., Washington, D.C., Aug. 1983, American Chemical Society, Washington, D.C., 1983; Abstr. MEDI, 1. 37. Yaksh, T. L., The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat, /. Clin. Pharmacol.,21, 334s, 1981. 38. Dykstra, L. A., Effects of morphine, levonantradol and N-methyllevonantradol on shock intensity discrimination, J. Clin. Pharmacol.,21, 341s, 1981. 39. Smith, J. B., Effects of morphine and two cannabinoid-related analgesics on responding under schedules of electric-shock titration, Fed. Proc., 39, 761, 1980. 40. Gilbert, P. E., A comparison of THC, nantradol, nabilone and morphine in the chronic spinal dog, J. Clin. Pharmacol.,2\, 311s, 1981. 41. Jain, A. K., Ryan, J. R., McMahon, F. G., and Smith, G., Evaluation of intramuscular levonantradol and placebo in acute postoperative pain, /. Clin. Pharmacol.,2[, 320s, 1981. 42. Lai, H., Bennett, D. A., Shearman, G. T., McCarten, M. D., Murphy, R., and Angeja, A., Effectiveness of nantradol in blocking narcotic withdrawal signs through nonnarcotic mechanisms, J. Clin. Pharmacol.,21, 361s, 1981. 43. Collier, H. O. J. and Roy, A. C., Morphine-like drugs inhibit the stimulation by E prostaglandins of cyclic AMP formation by rat brain homogenate, Nature (London), 248, 24, 1974. 44. Johnson, M. R., Schaaf, T. K., Constantine, J. W., and Hess, H.-J., Structure activity studies leading to a tissue-selective hypotensive prostaglandin analog, 13,14-dihydro-16-phenyl-w-tetranor PGE2, Prostaglandins, 20, 515, 1980. 45. Bordner, J., University of North Carolina, personal communication, 1979. 46. Edmonds, J. W. and Duax, W. L., Molecular conformation of prostaglandin Ez, Prostaglandins, 5, 275, 1974. 47. McCarthy, L. E. and Borison, H. L., Antiemetic activity of N-methyllevonantradol and nabilone in cisplatin-treated cats, J. Clin. Pharmacol.,21, 30s, 1981. 48. Cronin, C. M., Sallan, S. E., Gelber, R., Lucas, V. S., and Laszlo, J., Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy, J. Clin. Pharmacol.,21, 43s, 1981. 49. Embrey, M. P., Killer, K., and Mahendran, P., Termination of pregnancy by extraamniotic prostaglandins and the synergistic action of oxytocin, Adv. Biosci., 9, 507, 1973. 50. Craft, L, Oral prostaglandin E2 and amniotomy for induction of labor, Adv. Biosci., 9, 593, 1973. 51. Rich, W. M., Abdulhayoglu, G., and DiSaia, P. J., Methylprednisolone as an antiemetic during cancer chemotherapy — a pilot study, Gynecol. Oncol., 9, 193, 1980. 52. Home, W. C., Desacetyl-1-nantradol: a selective prostaglandin antagonist, Prostaglandins Leukotrienes and Med., 15, 129, 1984. 53. Hillard, C. J. and Bloom, A. S., Possible role of prostaglandins in the effects of the cannabinoids on adenylate cyclase activity, Eur. J. Pharmacol.,91, 21, 1983. 54. Loscher, W., 3-Mercaptopropionic acid: convulsant properties, effects on enzymes of the y-aminobutyrate system in mouse brain and antagonism by certain anticonvulsant drugs, aminooxyacetic acid and gabaculine, Biochem. Pharmacol.,28, 1397, 1979. 55. Revuelta, A. V., Cheney, D. L., Wood, P. L., and Costa, E., GABAergic mediation in the inhibition of hippocampal acetylcholine turnover rate elicited by A'-tetrahydrocannabinol, Neuropharmacology, 18, 525, 1979. 56. Leader, J. P., Koe, B. K., and Weissman, A., GABA-like actions of levonantradol, J. Clin. Pharmacol.,2\, 262s, 1981. 57. Koe, B. K. and Weissman, A., Facilitation of benzodiazepine binding by levonantradol, J. Clin. Pharmacol.,21, 397s, 1981. 58. Costa, E., Cheney, D. L., and Murray, T. F., Levonantradol-induced inhibition of acetylcholine turnover in rat hippocampus and striatum, J. Clin. Pharmacol.,21, 256s, 1981. 59. Koe, B. K., Milne, G. M., Weissman, A., Johnson, M. R., and Melvin, L. S., Enhancement of brain LHJFIunitrazepam binding and analgesic activity of synthetic cannabimimetics, Eur. J. Pharmacol., 109, 201, 1985. 60. Citron, M. L., Herman, T. S., Fossieck, B. E., Jr., Krasnow, S. H., Vreeland, F., and Harwood, S., Double blind, randomized, crossover study of the antiemetic effect of levonantradol (LVN) versus tetrahydrocannabinol (THC), Proc. Am. Assoc. Cancer Res., 24, 165, 1983. 61. Earhart, R. H. and Koeller, J. M., Levonantradol vs. prochlorperazine as parenteral antiemetics in cancer patients receiving cisplatin chemotherapy, Proc. Am. Assoc. Cancer Res., 24, 163, 1983. 62. Stuart-Harris, R. C., Mooney, C. A., and Smith, I. E., Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional antiemetic therapy, Clin. Oncol.,9, 143, 1983. 63. Stuart-Harris, R., Mooney, C., and Smith, I. E., Levonantradol (LN) in the treatment of chemotherapy induced nausea and vomiting, refractory to conventional anti-emetics, Br. J. Cancer, 47, 568, 1983. 64. Hutcheon, A. W., Palmer, J. B., Soukop, M., Cunningham, D., McArdle, C., Welsh, J., Stuart, F., Sangster, G., Kaye, S., Charlton, D., and Cash, H., A randomized multicenter single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy, Eur. J. Cancer Clin. Oncol., 19, 1087, 1983. 65. Gerhartz, H. H., Binsack, T., and Hiller, E., Levonantradol for the treatment of chemotherapyinduced nausea and vomiting, Klin. Wochenscfir.,61, 719, 1983. 66. Welsh, J., Stuart, F., Sangster, G., Milstead, R., Kaye, S., Cash, H., Charlton, D., and Caiman, K., Oral levonantradol in the control of cancer chemotherapy-induced emesis, Cancer Chemother. Pharmacol., 11, 66, 1983. 67. Sheidler, V. R., Ettinger, D. S., Diasio, R. B., Enterline, J. P., and Brown, M. D., Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine, /. Clin. Pharmacol.,24, 155, 1984. 68. Heim, M. E. and Queisser, W., Treatment of refractory cytostatic agent-induced vomiting with the synthetic cannabinoid levonantradol, Onkologie,S, 94, 1982. 69. Heim, M. E., Romer, W., and Queisser, W., Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting, J. Clin. Pharmacol., 21, 86s, 1981. 70. Diasio, R. B., Ettinger, D. S., and Satterwhite, B. E., Oral levonantradol in the treatment of chemotherapy-induced emesis: preliminary observations, J. Clin. Pharmacol.,21, 81s, 1981. 71. Laszlo, J., Lucas, V. S., Jr., Hanson, D. C., Cronin, C. M., and S. E. Sallan, Levonantradol for chemotherapy-induced emesis: phase I-II oral administration, J. Clin. Pharmacol., 21, 51s, 1981. 1. Shapiro, B. J., Tashkin, D. P., and Vachon, L., THC as a bronchodilator. Why bother?, Chest, 71, 558, 1977. 2. Perez-Reyes, N., Lipton, M. A., Timmous, M. C., Wall, M. E., Brine, D. R., and Davis, K. H., Pharmacology of orally administered A'-THC, /. Clin. Pharm. Ther., 14, 48, 1973. 3. Abboud, R. T. and Sanders, H. D., Effect of oral administration of A'-THC on airways mechanics in normal and asthmatic subjects, Chest, 70, 480, 1976. 4. Davies, B. H., Radcliffe, S., Seaton, A., and Graham, J. D. P., A trial of oral A'-THC in reversible airways obstruction, Thorax, 30, 80, 1975. 5. Perez Reyes, M., Timmons, M. C., Davis, K. H., and Wall, M. C., A comparison of the pharmacological activity in man of intravenously administered A'-tetrahydrocannabinol, cannabinol, and cannabidiol, Experientia,29, 1368, 1973. 6. Malit, L. A., Johnstone, R. E., Bourke, D. L, Kulp, R. A., Klein, V., and Smith, T. C., Intravenous A'-THC: effects on ventilatory control and cardiovascular dynamics, Anaesthesiology, 42, 666, 1975. 7. Smith, T. C. and Kulp, R. A., Respiratory and cardiovascular effects of A'-THC alone and in combination with oxymorphone, pentobarbital and diazepam, in Therapeutic Potential of Marijuana, Cohen, S. and Stillman, R. C., Eds., Plenum Press, New York, 1976, 123. 8. Olsen, J. L., Lodge, J. W., Shapiro, B. J., and Tashkin, D. P., An inhalation aerosol of A'-THC, J. Pharm. Pharmacol., 28, 86, 1976. 9. Williams, S. J., Hartley, J. P. R., and Graham, J. D. P., Bronchodilator effect of A'-THC administered by aerosol to asthmatic patients, Thorax, 31, 720, 1976. 10. Vachon, L., The smoke in marijuana smoking, N. Engl. J. Med., 294, 160, 1976. 11. Vachon, L., Fitzgerald, M. X., Solliday, N. H., Gould, I. A., and Gaensler, E. A., Single dose effect of marijuana smoke, N. Engl. J. Med., 288, 985, 1973. 12. Tashkin, D. R., Shapiro, B. J., and Frank, I. M., Acute pulmonary physiological effects of smoked marijuana and oral A'-tetrahydrocannabinol in healthy young men, New Engl. J. Med., 289, 336, 1973. 13. Tashkin, D. P., Shapiro, B. J., Lee, Y. E., and Harper, C. E., Effects of smoked marijuana in experimentally induced asthma, Am. Rev. Resp. Dis., 112, 337, 1975. 14. Tashkin, D. P., Shapiro, B. J., Lee, Y. E., and Harper, C. E., Subacute effects of heavy marijuana smoking on pulmonary function in healthy men, New Engl. J. Med., 294, 125, 1976. 15. Avakian, E. V., Horvath, S. M., Michael, E. D., and Jacobs, S., Effect of marijuana on cardiorespiratory responses to submaximal exercise, din. Pharmacol. Ther.,26, 77, 1979. 16. Tashkin, D. P., Calvarese, B. M., Simmons, S., and Shapiro, B. J., Respiratory status of seventy four habitual marijuana smokers, Chest, 78, 699, 1980. 17. Tashkin, D. P., Calv
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090
Hempseed as a nutritional resource: An overview
Callaway, J. C. (2004) · Euphytica · doi:10.1007/s10681-004-4811-6 · Cited by 910
Cannabinoid pharmacology: the first 66 years
Pertwee, R. G. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706406 · Cited by 782
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications
Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S., & Huestis, M. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.005 · Cited by 709
Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells.
Mackie, K., & Hille, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3825 · Cited by 694
Molecular cloning of a human cannabinoid receptor which is also expressed in testis
Gérard, C. M., Mollereau, C., Vassart, G., & Parmentier, M. (1991) · Biochemical Journal · doi:10.1042/bj2790129 · Cited by 687
Mailleux, P., & Vanderhaeghen, J.-J. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90409-u · Cited by 664
Russo, E., & Guy, G. W. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 610
HU-308: A specific agonist for CB 2 , a peripheral cannabinoid receptor
Hanuš, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R. G., Ross, R. A., Mechoulam, R., & Fride, E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14228 · Cited by 571
Cannabis: pharmacology and toxicology in animals and humans
ADAMS, I. B., & MARTIN, B. R. (1996) · Addiction · doi:10.1046/j.1360-0443.1996.911115852.x · Cited by 570
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Neuronal localization of cannabinoid receptors in the basal ganglia of the rat
Herkenham, M., Lynn, A. B., de Costa, B. R., & Richfield, E. K. (1991) · Brain Research · doi:10.1016/0006-8993(91)90970-7 · Cited by 515
Cannabidiol: An Overview of Some Pharmacological Aspects
Mechoulam, R., Parker, L. A., & Gallily, R. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb05998.x · Cited by 508
Structure−Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists
Lan, R., Liu, Q., Fan, P., Lin, S., Fernando, S. R., McCallion, D., Pertwee, R., & Makriyannis, A. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980363y · Cited by 447
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs
Martin, B. R., Compton, D. R., Thomas, B. F., Prescott, W. R., Little, P. J., Razdan, R. K., Johnson, M. R., Melvin, L. S., Mechoulam, R., & Susan J., W. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90349-7 · Cited by 409
Early phytocannabinoid chemistry to endocannabinoids and beyond
Mechoulam, R., Hanuš, L. O., Pertwee, R., & Howlett, A. C. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3811 · Cited by 393
The therapeutic potential of cannabis
Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00381-8 · Cited by 343
Controlled clinical trial of cannabidiol in Huntington's disease
Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., & Schram, K. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90386-g · Cited by 320
Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond
Pertwee, R. G. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00108.x · Cited by 314
The cannabinoid receptor: biochemical, anatomical and behavioral characterization
Howlett, A. C., Bidaut-Russell, M., Devane, W. A., Melvin, L. S., Johnson, M. R., & Herkenham, M. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90124-s · Cited by 311
A historical overview of chemical research on cannabinoids
Mechoulam, R., & Hanuš, L. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00184-5 · Cited by 282
Cannabinoid receptors and the regulation of immune response
Berdyshev, E. V. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00195-x · Cited by 280
The case for medical marijuana in epilepsy
Maa, E., & Figi, P. (2014) · Epilepsia · doi:10.1111/epi.12610 · Cited by 275
BISOGNO, T., SEPE, N., MELCK, D., MAURELLI, S., PETROCELLIS, L. D., & MARZO, V. D. (1997) · Biochemical Journal · doi:10.1042/bj3220671 · Cited by 275
Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271
Therapeutic aspects of cannabis and cannabinoids
Robson, P. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.2.107 · Cited by 265
Huffman, J. W., Zengin, G., Wu, M.-J., Lu, J., Hynd, G., Bushell, K., Thompson, A. L. S., Bushell, S., Tartal, C., Hurst, D. P., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.09.050 · Cited by 259
Cannabis use in HIV for pain and other medical symptoms
Woolridge, E., Barton, S., Samuel, J., Osorio, J., Dougherty, A., & Holdcroft, A. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.07.011 · Cited by 208
Klein, C., Karanges, E., Spiro, A., Wong, A., Spencer, J., Huynh, T., Gunasekaran, N., Karl, T., Long, L. E., Huang, X.-F., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2342-0 · Cited by 206
Cannabis and the developing brain: Insights from behavior
Trezza, V., Cuomo, V., & Vanderschuren, L. J. M. J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.058 · Cited by 131
Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., & Pölz, W. (2006) · Wiener klinische Wochenschrift · doi:10.1007/s00508-006-0611-4 · Cited by 96
Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics
Yu, H. S., Gao, C., Lupyan, D., Wu, Y., Kimura, T., Wu, C., Jacobson, L., Harder, E., Abel, R., & Wang, L. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00268 · Cited by 39
Metadata
- Venue
- Chapman & Hall/CRC eBooks
- Publisher
- Chapman and Hall/CRC
- Published
- 2019-06-13
- OpenAlex
- W3018792442
- Cited by
- 311
- References
- 0
- FWCI
- 3.92
- Type
- book
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.